JP2019529534A - 錠剤組成物 - Google Patents

錠剤組成物 Download PDF

Info

Publication number
JP2019529534A
JP2019529534A JP2019533300A JP2019533300A JP2019529534A JP 2019529534 A JP2019529534 A JP 2019529534A JP 2019533300 A JP2019533300 A JP 2019533300A JP 2019533300 A JP2019533300 A JP 2019533300A JP 2019529534 A JP2019529534 A JP 2019529534A
Authority
JP
Japan
Prior art keywords
tablet
trifluoromethyl
amino
pyridin
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019533300A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019529534A5 (enExample
Inventor
エス． ブハット スレエニバス
エス． ブハット スレエニバス
バーンサイド スコット
バーンサイド スコット
パリクフ ダルシャン
パリクフ ダルシャン
グ チョング‐フイ
グ チョング‐フイ
アルタフ サイド
アルタフ サイド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2019529534A publication Critical patent/JP2019529534A/ja
Publication of JP2019529534A5 publication Critical patent/JP2019529534A5/ja
Priority to JP2022150798A priority Critical patent/JP7487270B2/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2019533300A 2016-09-07 2017-09-06 錠剤組成物 Pending JP2019529534A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022150798A JP7487270B2 (ja) 2016-09-07 2022-09-22 錠剤組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662384643P 2016-09-07 2016-09-07
US62/384,643 2016-09-07
US201762535162P 2017-07-20 2017-07-20
US62/535,162 2017-07-20
PCT/US2017/050202 WO2018048847A1 (en) 2016-09-07 2017-09-06 Tablet compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022150798A Division JP7487270B2 (ja) 2016-09-07 2022-09-22 錠剤組成物

Publications (2)

Publication Number Publication Date
JP2019529534A true JP2019529534A (ja) 2019-10-17
JP2019529534A5 JP2019529534A5 (enExample) 2020-10-22

Family

ID=59895401

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019533300A Pending JP2019529534A (ja) 2016-09-07 2017-09-06 錠剤組成物
JP2022150798A Active JP7487270B2 (ja) 2016-09-07 2022-09-22 錠剤組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022150798A Active JP7487270B2 (ja) 2016-09-07 2022-09-22 錠剤組成物

Country Status (16)

Country Link
US (3) US11389454B2 (enExample)
EP (1) EP3509570A1 (enExample)
JP (2) JP2019529534A (enExample)
KR (1) KR102498693B1 (enExample)
CN (2) CN109715143A (enExample)
AU (1) AU2017324844B2 (enExample)
BR (1) BR112019004356A2 (enExample)
CA (1) CA3036053A1 (enExample)
CL (1) CL2019000573A1 (enExample)
CO (1) CO2019002092A2 (enExample)
EC (1) ECSP19015828A (enExample)
IL (1) IL265126B2 (enExample)
MX (1) MX392941B (enExample)
SG (1) SG11201901873PA (enExample)
WO (1) WO2018048847A1 (enExample)
ZA (1) ZA201901321B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3253746A1 (en) 2015-02-04 2017-12-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
KR102498693B1 (ko) * 2016-09-07 2023-02-10 셀진 코포레이션 정제 조성물
WO2020092894A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
WO2020092915A1 (en) * 2018-11-02 2020-05-07 Celgene Corporation Solid dispersions for treatment of cancer
WO2020092906A1 (en) * 2018-11-02 2020-05-07 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
WO2020239759A1 (en) * 2019-05-27 2020-12-03 Sandoz Ag Amorphous enasidenib in a stabilized form
US20220401450A1 (en) * 2019-11-14 2022-12-22 Celgene Corporation Pediatric formulations for treatment of cancer
EP4358942A1 (en) * 2021-06-23 2024-05-01 Blueprint Medicines Corporation Pharmaceutical compositions of an epidermal growth factor receptor inhibitor
WO2024008138A1 (zh) * 2022-07-07 2024-01-11 正大天晴药业集团股份有限公司 1,3,5-三嗪衍生物的药物组合

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015017821A2 (en) * 2013-08-02 2015-02-05 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2016053850A1 (en) * 2014-09-29 2016-04-07 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0771339B1 (en) * 1994-07-12 2003-10-15 BPSI Holdings, Inc. Dry moisture barrier film coating composition, method of coating substrates using the same and pharmaceutical tablets coated therewith
TW430561B (en) * 1995-12-20 2001-04-21 Gea Farmaceutisk Fabrik As Rapid release tablet composition comprising tolfenamic acid or a pharmaceutically acceptable salt thereof as active ingredient and a method of preparing such tablet
AR016827A1 (es) * 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
EP1416919A1 (en) * 2001-07-17 2004-05-12 Teva Pharmaceutical Industries Ltd. Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate
US20070010466A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
EP3566697B1 (en) * 2009-11-09 2024-09-11 Wyeth LLC Tablet formulations of neratinib maleate
JP2013536231A (ja) * 2010-08-23 2013-09-19 バーテックス ファーマシューティカルズ インコーポレイテッド （ｒ）−１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）−ｎ−（１−（２，３−ジヒドロキシプロピル）−６−フルオロ−２−（１−ヒドロキシ−２−メチルプロパン−２−イル）−１ｈ−インドール−５−イル）シクロプロパンカルボキサミドを含む医薬組成物およびその投与
SMT201800334T1 (it) 2012-01-06 2018-09-13 Agios Pharmaceuticals Inc Composti terapeuticamente attivi e loro metodi di utilizzo
MX375030B (es) 2013-07-11 2025-03-06 Agios Pharmaceuticals Inc Compuestos de n,6-bis(aril o heteroaril)-1,3,5-triazin-2,4-diamina como inhibidores de idh2 mutantes para el tratamiento de cancer.
KR102316886B1 (ko) * 2013-08-02 2021-10-19 아지오스 파마슈티컬스 아이엔씨. 치료학적 활성 화합물 및 이의 사용방법
WO2015018060A1 (en) 2013-08-09 2015-02-12 Agios Pharmaceuticals, Inc. Crystalline forms of therapeutically active compounds and use thereof
EP3253746A1 (en) 2015-02-04 2017-12-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3302442B1 (en) * 2015-06-03 2024-10-16 Triastek, Inc. Dosage forms and use thereof
CN108349933A (zh) 2015-08-05 2018-07-31 安吉奥斯医药品有限公司 制备6-(芳基或杂芳基)-1,3,5-三嗪-2,4-二醇和6-(芳基或杂芳基)-1,3,5-三嗪-2,4-二胺的方法
CA3002029A1 (en) 2015-10-15 2017-04-20 Celgene Corporation Combination therapy for treating malignancies
JP2018534288A (ja) 2015-10-15 2018-11-22 アジオス ファーマシューティカルズ， インコーポレイテッド 悪性腫瘍の治療のための併用療法
MA43374A (fr) 2015-12-04 2018-10-10 Agios Pharmaceuticals Inc Méthodes de traitement de tumeurs malignes
CA3015753A1 (en) 2016-02-26 2017-08-31 Celgene Corporation Idh2 inhibitors for the treatment of haematological maligancies and solid tumours
KR102498693B1 (ko) * 2016-09-07 2023-02-10 셀진 코포레이션 정제 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015017821A2 (en) * 2013-08-02 2015-02-05 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2016053850A1 (en) * 2014-09-29 2016-04-07 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Also Published As

Publication number Publication date
IL265126A (enExample) 2019-04-30
CN109715143A (zh) 2019-05-03
JP2022191265A (ja) 2022-12-27
BR112019004356A2 (pt) 2019-05-28
CO2019002092A2 (es) 2019-05-31
US11389454B2 (en) 2022-07-19
ZA201901321B (en) 2023-12-20
AU2017324844B2 (en) 2023-05-11
CL2019000573A1 (es) 2019-07-19
US20220323447A1 (en) 2022-10-13
IL265126B1 (en) 2023-08-01
KR102498693B1 (ko) 2023-02-10
KR20190045199A (ko) 2019-05-02
US20180064715A1 (en) 2018-03-08
ECSP19015828A (es) 2019-03-29
NZ751112A (en) 2024-03-22
CN120501712A (zh) 2025-08-19
CA3036053A1 (en) 2018-03-15
SG11201901873PA (en) 2019-03-28
EP3509570A1 (en) 2019-07-17
AU2017324844A1 (en) 2019-03-21
US20240335450A1 (en) 2024-10-10
WO2018048847A1 (en) 2018-03-15
IL265126B2 (en) 2023-12-01
MX392941B (es) 2025-03-24
JP7487270B2 (ja) 2024-05-20
MX2019002697A (es) 2019-10-04

Similar Documents

Publication Publication Date Title
JP7487270B2 (ja) 錠剤組成物
US20250109136A1 (en) Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase
JP6892448B2 (ja) 悪性腫瘍の処置の方法
JP2021102630A (ja) 血液学的悪性疾患および固形腫瘍の処置のためのｉｄｈ１阻害剤
AU2015229214B2 (en) Pharmaceutical compositions of therapeutically active compounds
JP2016531151A (ja) レファメチニブを含有する医薬組成物
ES3017432T3 (en) Pediatric formulations for treatment of cancer
JP2018502863A (ja) 白血病の治療のための４−（４−フルオロ−２−メトキシフェニル）−ｎ−｛３−［（ｓ−メチルスルホンイミドイル）メチル］フェニル｝−１，３，５−トリアジン−２−アミンの使用
EA049168B1 (ru) Таблетка для лечения пролиферативного заболевания
US12215094B2 (en) Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
AU2021275620A1 (en) Pharmaceutical formulations and their preparations for treatment of cancer
EA039805B1 (ru) Комбинированная терапия для лечения злокачественных опухолей

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200903

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200903

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210629

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210630

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220524

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220922

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20221004

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20221004

C27A Decision to dismiss

Free format text: JAPANESE INTERMEDIATE CODE: C2711

Effective date: 20221122

C032 Notice prior to dismissal

Free format text: JAPANESE INTERMEDIATE CODE: C032

Effective date: 20230110

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20230110